These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 27564657)
21. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. Marar TT; Boffa MB J Thromb Haemost; 2016 Apr; 14(4):772-83. PubMed ID: 26816270 [TBL] [Abstract][Full Text] [Related]
22. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. Foley JH; Kim P; Nesheim ME J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711 [TBL] [Abstract][Full Text] [Related]
23. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823 [TBL] [Abstract][Full Text] [Related]
24. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Marx PF; Bouma BN; Meijers JC Biochemistry; 2002 Jan; 41(4):1211-6. PubMed ID: 11802720 [TBL] [Abstract][Full Text] [Related]
25. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Bajzar L; Jain N; Wang P; Walker JB Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538 [TBL] [Abstract][Full Text] [Related]
26. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia? Dusse LM; Cooper AJ; Lwaleed BA Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758 [TBL] [Abstract][Full Text] [Related]
28. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237 [TBL] [Abstract][Full Text] [Related]
29. [The TAFI system. The new role of fibrinolysis]. Dempfle CE Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767 [TBL] [Abstract][Full Text] [Related]
30. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors. Gils A; Ceresa E; Macovei AM; Marx PF; Peeters M; Compernolle G; Declerck PJ J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512 [TBL] [Abstract][Full Text] [Related]
31. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. Boffa MB; Wang W; Bajzar L; Nesheim ME J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053 [TBL] [Abstract][Full Text] [Related]
32. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Boffa MB; Koschinsky ML Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488 [TBL] [Abstract][Full Text] [Related]
33. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701 [TBL] [Abstract][Full Text] [Related]
34. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893 [TBL] [Abstract][Full Text] [Related]
35. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Bajzar L; Nesheim ME; Tracy PB Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928 [TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Guimarães AH; Rijken DC Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222 [TBL] [Abstract][Full Text] [Related]
37. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis. Morishima Y; Kamisato C; Honda Y J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790 [TBL] [Abstract][Full Text] [Related]
38. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. Wang W; Nagashima M; Schneider M; Morser J; Nesheim M J Biol Chem; 2000 Jul; 275(30):22942-7. PubMed ID: 10801821 [TBL] [Abstract][Full Text] [Related]
39. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. Bazzi ZA; Balun J; Cavallo-Medved D; Porter LA; Boffa MB Clin Exp Metastasis; 2017 Feb; 34(2):155-169. PubMed ID: 28124276 [TBL] [Abstract][Full Text] [Related]
40. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease. Bridge KI; Bollen L; Zhong J; Hesketh M; Macrae FL; Johnson A; Philippou H; Scott DJ; Gils A; Ariёns RAS J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]